FDA
-
-
-
-
-
-
-
Jazz Pharmaceuticals presents Xywav sleep disorder data at SLEEP 2026 conference
-
-
-
-
-
-
-
Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally
-
-
-
-
-
-
-
Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026
-
-
-
-
-
-
-
Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annua
-
-
-
-
-
-
-
Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso™ (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025
-
-
-
-
-
-
-
Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych
-
-
-
-
-
-
-
FDA approves Jazz Pharmaceuticals' dordaviprone for rare brain cancer
-
329,940 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

